000 01436 a2200421 4500
005 20250512065423.0
264 0 _c19860602
008 198606s 0 0 eng d
022 _a0736-0118
024 7 _a10.1007/BF02934572
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aCunningham, D
245 0 0 _aTNO-6 has no effect in gastrointestinal cancer: N-acetyl-glucosaminidase shows renal damage.
_h[electronic resource]
260 _bMedical oncology and tumor pharmacotherapy
_c1986
300 _a25-8 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAcetylglucosaminidase
_xurine
650 0 4 _aAdenocarcinoma
_xdrug therapy
650 0 4 _aColonic Neoplasms
_xdrug therapy
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aKidney Diseases
_xchemically induced
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aOrganoplatinum Compounds
_xadverse effects
650 0 4 _aRectal Neoplasms
_xdrug therapy
650 0 4 _aStomach Neoplasms
_xdrug therapy
700 1 _aSoukop, M
700 1 _aGilchrist, N L
700 1 _aForrest, G J
700 1 _aCarter, D C
700 1 _aMcArdle, C S
700 1 _aKaye, S B
700 1 _aDobbie, J W
700 1 _aSmith, M
773 0 _tMedical oncology and tumor pharmacotherapy
_gvol. 3
_gno. 1
_gp. 25-8
856 4 0 _uhttps://doi.org/10.1007/BF02934572
_zAvailable from publisher's website
999 _c3708209
_d3708209